Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + erlotinib + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A multi-agent oncology regimen combining the anti-VEGF monoclonal antibody bevacizumab, the EGFR tyrosine kinase inhibitor erlotinib, the taxane chemotherapy docetaxel, and the corticosteroid prednisone. Mechanistically, bevacizumab inhibits angiogenesis by neutralizing VEGF-A; erlotinib selectively inhibits EGFR tyrosine kinase signaling; docetaxel stabilizes microtubules to inhibit mitosis; and prednisone provides anti-inflammatory and palliative effects and is standard with docetaxel in prostate cancer. This combination has been explored in clinical research settings, notably in metastatic castration-resistant prostate cancer where bevacizumab has been added to standard docetaxel + prednisone backbones; erlotinib has been studied with bevacizumab in other tumor contexts. The regimen is investigational as a four-drug combination and is not an approved fixed-combination product.
- Other names
- bevacizumab plus erlotinib plus docetaxel plus prednisonebevacizumab/erlotinib/docetaxel/prednisone
02
Targets
GR (Glucocorticoid receptor)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on bevacizumab + erlotinib + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + erlotinib + docetaxel + prednisone.